These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1049 related articles for article (PubMed ID: 10952840)

  • 21. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.
    Schiele F; Vuillemenot A; Kramarz P; Kieffer Y; Soria J; Soria C; Camez A; Mirshahi MC; Bassand JP
    Thromb Haemost; 1994 May; 71(5):558-62. PubMed ID: 8091380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.
    Jun L; Arnout J; Vanhove P; Dol F; Lormeau JC; Herbert JM; Collen D; Van de Werf F
    Coron Artery Dis; 1995 Mar; 6(3):257-63. PubMed ID: 7788040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
    Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S;
    Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
    Esslinger HU; Haas S; Maurer R; Lassmann A; Dübbers K; Müller-Peltzer H
    Thromb Haemost; 1997 May; 77(5):911-9. PubMed ID: 9184402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease.
    Oldgren J; Fellenius C; Boman K; Jansson JH; Nilsson TK; Wallentin L; Siegbahn A
    J Intern Med; 2005 Nov; 258(5):420-7. PubMed ID: 16238677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
    Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
    Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome.
    Ulrich-Möckel NV; Riehle M; Vollert J; Heller G; Störk T; Riess H; Müller C; Frei U; Möckel M
    Biomarkers; 2009 Aug; 14(5):311-6. PubMed ID: 19552570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative efficacy of once daily parnaparin and unfractionated heparin in unstable angina pectoris: PRIME CARE study.
    PRIME CARE Study Investigators Group
    Indian Heart J; 2005; 57(6):648-54. PubMed ID: 16521631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship of cardiac troponin T and procoagulant activity in unstable angina.
    Giannitsis E; Bardorff MM; Schweikart S; Wiegand U; Kampmann M; Katus HA
    Thromb Haemost; 2000 Feb; 83(2):224-8. PubMed ID: 10739377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Pilot Study: evaluation of acute and long-term therapies for patients with acute coronary syndromes without ST elevation.
    Anand SS
    Am J Cardiol; 1999 Sep; 84(5A):13M-19M. PubMed ID: 10505538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antithrombin therapy in acute coronary syndromes].
    Maseri A; Andreotti F; Biasucci LM; Rebuzzi AG
    Cardiologia; 1994 Dec; 39(12 Suppl 1):7-13. PubMed ID: 7634317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators.
    Serruys PW; Herrman JP; Simon R; Rutsch W; Bode C; Laarman GJ; van Dijk R; van den Bos AA; Umans VA; Fox KA
    N Engl J Med; 1995 Sep; 333(12):757-63. PubMed ID: 7643882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardial infarction.
    Bassand JP; Cariou R; Grollier G; Kragten J; Wolf JE; Heyndrickx GR
    Semin Thromb Hemost; 1999; 25 Suppl 2():69-75. PubMed ID: 10440428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
    Pleym H; Videm V; Wahba A; Asberg A; Amundsen T; Bjella L; Dale O; Stenseth R
    Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the antithrombotic effect of the new recombinant hirudin HBW 023 and heparin in small arteries and veins.
    Zhang B; Wieslander JB
    Microsurgery; 1996; 17(2):89-96. PubMed ID: 8914063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial.
    Topol EJ; Fuster V; Harrington RA; Califf RM; Kleiman NS; Kereiakes DJ; Cohen M; Chapekis A; Gold HK; Tannenbaum MA
    Circulation; 1994 Apr; 89(4):1557-66. PubMed ID: 8149521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of the antithrombotlic effect and safety between intravenous nadroparin and unfractionated heparin in patients undergoing percutaneous coronary intervention].
    Zhu JH; Qiu YG; Chen JZ; Zhang FR; Fu GS; Shen FR; Huang WJ; Wang JA; Zhao LL; Tao QM; Zheng LR
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Apr; 33(4):335-9. PubMed ID: 15932664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial.
    Giugliano RP; Wiviott SD; Stone PH; Simon DI; Schweiger MJ; Bouchard A; Leesar MA; Goulder MA; Deitcher SR; McCabe CH; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(25):2398-407. PubMed ID: 17599602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.